David C. Perlman, MD
CDUHR - Director, Infectious Disease Epidemiology and Social-behavioral Theory Core
Mount Sinai Health System - Professor of Medicine, Icahn School of Medicine
Mount Sinai Health System - Chief, Infectious Diseases, Mount Sinai Beth Israel
MD, Medicine, Albert Einstein College of Medicine
BA. Biochemistry & Anthropology, Dartmouth College
Research Interests
HIV, HCV, IDUs, Diagnosis and treatment
David Perlman has over 20 years’ experience in HIV, HCV, TB and STIs and remains active as a clinician in these areas. He has served as principal investigator on multi-center trials within NIAID’s AIDS Clinical Trials group, and on R01 grants from NIDA. He has served on NIH study sections, CDC consensus panels, and committees within the ACTG, the NYS DOH AIDS Institute, and the NYC DOMH. Dr. Perlman’s earlier work focused on studies of the epidemiology of tuberculosis among drug users, and on health care delivery models and behavioral and structural interventions to facilitate adherence to the TB and HIV/TB care continuum. Dr. Perlman’s recent work has focused on studies of barriers and facilitators of HIV and HCV testing and care among racial and ethnic minorities, high risk heterosexuals, and people who use drugs, and more broadly on studies of strategies to improve HIV and HIV/HCV care continua and prevention programming for these populations.
Principal Investigator, Hepatitis Care Coordination in Methadone Treatment. Completed


Frost MC, Austin EJ, Corcorran MA, Briggs ES, Behrends CN, Juarez AM, Frank ND, Healy E, Prohaska SM, LaKosky PA, Kapadia SN, Perlman DC, Schackman BR, Des Jarlais DC, Williams EC, Glick SN (2022).
Responding to a surge in overdose deaths: Perspectives from US syringe services programs
Harm Reduction Journal, 19 (1), 79. doi: 10.1186/s12954-022-00664-y. PMCID: PMC9295104.

Friedman SR, Williams LD, Williams LD, Jordan AE, Walters S, Perlman DC, Mateu-Gelabert P, Nikolopoulos GK, Khan MR, Peprah E, Ezell J (2022).
Toward a theory of the underpinnings and vulnerabilities of structural racism: Looking upstream from disease inequities among people who use drugs
International Journal of Environmental Research and Public Health, 19 (12), 7453. doi: 10.3390/ijerph19127453. PMCID: PMC9224240.

Walters SM, Perlman DC, Guarino H, Mateu-Gelabert P, Frank D (2022).
Lessons from the first wave of COVID-19 for improved medications for opioid use disorder (MOUD) treatment: Benefits of easier access, extended take homes, and new delivery modalities
Substance Use and Misuse, 57 (7), 1144-1153. doi: 10.1080/10826084.2022.2064509.

Behrends CN, Lu X, Corry GJ, LaKosky P, Prohaska SM, Glick SN, Kapadia SN, Perlman DC, Schackman BR, Des Jarlais DC (2022).
Harm reduction and health services provided by syringe services programs in 2019 and subsequent impact of COVID-19 on services in 2020
Drug and Alcohol Dependence, 232, 109323. doi: 10.1016/j.drugalcdep.2022.109323. PMCID: PMC8772135.

Gutkind S, Starbird LE, Murphy SM, Teixeira PA, Gooden LK, Matheson T, Feaster DJ, Jain MK, Masson CL, Perlman DC, Del Rio C, Metsch LR, Schackman BR (2022).
Cost of hepatitis C care facilitation for HIV/hepatitis C co-infected people who use drugs
Drug and Alcohol Dependence, 232, 109265. doi: 10.1016/j.drugalcdep.2022.109265. PMCID: PMC9238179.

Dr. Perlman's MyBibliography Profile